Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Alpha 1 Antitrypsin Deficiency Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global alpha 1 antitrypsin deficiency treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. 

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor’s blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha 1 antitrypsin deficiency treatment market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, route of administration and end user.

Breakup by Treatment Type:

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Others
     

Breakup by Route of Administration:

  • Parenteral
  • Inhalation
  • Oral
     

Breakup by End User:

  • Hospitals
  • Specialty Clinics
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, Boehringer Ingelheim GmbH, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments, Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Report Coverages:

Report Features Details
Base Year of the Analysis 2020
Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Treatment Type, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AstraZeneca PLC, Boehringer Ingelheim GmbH, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments, Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global alpha 1 antitrypsin deficiency treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alpha 1 antitrypsin deficiency treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alpha 1 antitrypsin deficiency treatment market and who are the key players?
  • What is the degree of competition in the industry?

1   Preface
2   Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

    4.1    Overview
    4.2    Key Industry Trends
5   Global Alpha 1 Antitrypsin Deficiency Treatment Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Treatment Type
    6.1    Augmentation Therapy
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Bronchodilators
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Corticosteroids
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Oxygen Therapy
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Others
        6.5.1 Market Trends
        6.5.2 Market Forecast
7   Market Breakup by Route of Administration
    7.1    Parenteral
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Inhalation
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Oral
        7.3.1 Market Trends
        7.3.2 Market Forecast
8   Market Breakup by End User
    8.1    Hospitals
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Specialty Clinics
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Others
        8.3.1 Market Trends
        8.3.2 Market Forecast
9   Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10  SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11  Value Chain Analysis
12  Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13  Price Analysis
14  Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    AstraZeneca PLC 
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio 
        14.3.2    Boehringer Ingelheim GmbH
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio 
        14.3.3    CSL Limited 
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio 
        14.3.4    GlaxoSmithKline Plc
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio 
        14.3.5    Grifols S.A.
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio 
        14.3.6    Kamada Ltd.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio 
        14.3.7    LFB Biomedicaments
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio 
        14.3.8    Pfizer Inc.
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio 
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis
        14.3.9    Takeda Pharmaceutical Company Limited
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio 
           14.3.9.3 Financials
        14.3.10   Teva Pharmaceutical Industries Ltd.
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio 

List of Figures

Figure 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Major Drivers and Challenges
Figure 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Treatment Type (in %), 2020
Figure 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Route of Administration (in %), 2020
Figure 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by End User (in %), 2020
Figure 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Breakup by Region (in %), 2020
Figure 8: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 9: Global: Alpha 1 Antitrypsin Deficiency Treatment (Augmentation Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 10: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market: Sales Value (in Million US$), 2015 & 2020
Figure 11: Global: Alpha 1 Antitrypsin Deficiency Treatment (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 12: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2015 & 2020
Figure 13: Global: Alpha 1 Antitrypsin Deficiency Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 14: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 15: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oxygen Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 16: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 17: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 18: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market: Sales Value (in Million US$), 2015 & 2020
Figure 19: Global: Alpha 1 Antitrypsin Deficiency Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 20: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market: Sales Value (in Million US$), 2015 & 2020
Figure 21: Global: Alpha 1 Antitrypsin Deficiency Treatment (Inhalation) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 22: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market: Sales Value (in Million US$), 2015 & 2020
Figure 23: Global: Alpha 1 Antitrypsin Deficiency Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 24: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
Figure 25: Global: Alpha 1 Antitrypsin Deficiency Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 26: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2015 & 2020
Figure 27: Global: Alpha 1 Antitrypsin Deficiency Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 28: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 29: Global: Alpha 1 Antitrypsin Deficiency Treatment (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 30: North America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 31: North America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 32: United States: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: United States: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: Canada: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: Asia Pacific: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: China: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: China: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 41: Japan: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 42: India: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 43: India: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 44: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 45: South Korea: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 46: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 47: Australia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 48: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 49: Indonesia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 50: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 51: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 52: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 53: Europe: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 54: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 55: Germany: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 56: France: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 57: France: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 58: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 59: United Kingdom: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 60: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 61: Italy: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 62: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 63: Spain: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 64: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 65: Russia: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 66: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 67: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 68: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 69: Latin America: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 70: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 71: Brazil: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 72: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 73: Mexico: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 74: Others: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 75: Others: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 76: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market: Sales Value (in Million US$), 2015 & 2020
Figure 77: Middle East and Africa: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 78: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: SWOT Analysis
Figure 79: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Value Chain Analysis
Figure 80: Global: Alpha 1 Antitrypsin Deficiency Treatment Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2021-2026
Table 3: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
Table 4: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by End User (in Million US$), 2021-2026
Table 5: Global: Alpha 1 Antitrypsin Deficiency Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 6: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Structure
Table 7: Global: Alpha 1 Antitrypsin Deficiency Treatment Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links